Cullinan Therapeutics Inc. has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for CLN-049, a novel FLT3xCD3 T cell engager, for the treatment of relapsed/refractory acute myeloid leukemia (AML). The Fast Track status was granted based on promising efficacy and favorable safety data from a Phase 1 study in heavily pre-treated patients, highlighting the potential of CLN-049 to address a broad population of AML patients with limited treatment options.